Cridanimod

Summary

Cridanimod (CHEMBL1569545) is a phase-3 clinical-stage small molecule (ATC L03AX18); indicated across 3 conditions including endometrial carcinoma and endometrium neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: L03AX18
• Indications: 3 conditions
• Clinical trials: 3
• Chemistry: 253.25 Da · C15H11NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1569545
Name	Cridanimod
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	38072
ATC	L03AX18
Molecular formula	C15H11NO3
Molecular weight	253.25
InChIKey	UOMKBIIXHQIERR-UHFFFAOYSA-N

SMILES: C1=CC=C2C(=C1)C(=O)C3=CC=CC=C3N2CC(=O)O

IUPAC name: 2-(9-oxoacridin-10-yl)acetic acid

Also known as: Cridanimod, SID50086600, SID29217965, SID56422767, SID144205901, SID170466071, CRIDANIMOD, Cycloferon, cridanimod

Patent coverage: 288 distinct patent families (680 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 441 (65%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Fructose-bisphosphate aldolase, Ferritin light chain, Trypsin, Alpha-galactosidase A, Stimulator of interferon genes protein, Stimulator of interferon genes protein.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 8 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q3TBT3	5.48	Kd	3300	nM	CHEMBL_ACT_19004324
Q3TBT3	5.46	Kd	3500	nM	CHEMBL_ACT_19125334
Q3TBT3	5.46	Kd	3500	nM	CHEMBL_ACT_24734156
P00761	5.15	AC50	7069	nM	CHEMBL_ACT_5562128

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
endometrial carcinoma	2	MONDO:0002447	EFO:1001512
endometrium neoplasm	2	MONDO:0021251	MONDO:0011962
neoplasm	2	MONDO:0005070	EFO:0000616

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE2	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06183229	PHASE3	COMPLETED	Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza
NCT02064725	PHASE2	UNKNOWN	Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA
NCT03077698	PHASE2	TERMINATED	An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).